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Abstract  17 
The separation of some zwitterionic, basic and neutral antibiotic and antiretroviral compounds was 18 
studied using hydrophilic interaction chromatography (HILIC) on bare silica, bonded amide and urea 19 
superficially porous phases. The differences in the selectivity and retentivity of these stationary 20 
phases were evaluated for compounds with widely different physicochemical properties (logD -3.43 21 
to 2.41 at w
w
pH 3.0). The mobile phase was acetonitrile-ammonium formate buffered at low w
w
pH. 22 
Compounds containing quinolone and serine groups showed poor peak shapes on all columns, 23 
attributed to metal-oxide interactions with system metals. Peak shapes were improved by addition 24 
of citrate buffers. Gradient elution, particularly with regard to column equilibration, was also studied 25 
due to the large differences in retention factors observed under isocratic conditions. Full 26 
equilibration in HILIC was slow for both ionogenic and neutral solutes, requiring as much as ~40 27 
column volumes. However, highly repeatable partial equilibration, suitable for gradient elution, was 28 
achieved in only a few minutes. Pronounced selectivity differences in the separations were shown 29 
dependent on the partial equilibration time.  30 
 31 
 32 
Keywords: HILIC; antibiotics; antiretrovirals; peak shape; gradient elution. 33 
  34 
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1. Introduction 36 
Hydrophilic interaction chromatography (HILIC) is becoming widespread in application areas 37 
such as pharmaceutical [1], metabolite profiling [2,3], clinical [4] and environmental analysis [5]. It is 38 
a particularly useful technique when dealing with highly polar and/or ionogenic compounds that can 39 
give rise to poor retention or peak shape in reversed-phase chromatography [6]. In HILIC, retention 40 
is thought to be due to varying combinations of partitioning, electrostatic (ionic) and adsorption 41 
interactions [7]. Usually, the mobile phase is a water-miscible aprotic solvent such as acetonitrile 42 
(typically > 60% v/v) combined with a soluble aqueous buffer. It is now widely accepted that a major 43 
retention contribution is partitioning that occurs between a pseudo-immobilised water layer that 44 
persists at the stationary phase surface and the bulk mobile phase [8–11]. Ionic and adsorption 45 
interactions can also exist between free silanol and/or polar bonded groups on the stationary phase 46 
with charged moieties and hydrogen bonding sites on the solute. Attempts have been made to 47 
identify the differences between HILIC stationary phases in order to elucidate those that are of most 48 
use to the practitioner [12–14]. Furthermore, attempts at modelling retention [15,16] in HILIC have 49 
been made in order to facilitate optimisation and method development. HILIC has many advantages 50 
over RP such as improved desolvation and sensitivity with nebuliser-based detectors [17–20], lower 51 
operating pressures at a given linear velocity [6,21], superior peak shapes and column performance 52 
with basic compounds [6,22] as well as the possibility to achieve significantly different selectivity 53 
[23]. 54 
HILIC is a useful technique in the clinical laboratory, particularly with regards to therapeutic drug 55 
monitoring (TDM) [4,24]. TDM is necessary for obtaining accurate patient serum concentrations of a 56 
given drug in order to optimise the dosage levels; this ensures maximum efficacy as well as 57 
minimizing the potential for adverse toxic events. Adams et al. [25] reviewed the adoption of HILIC 58 
for the measurement of aminoglycoside, β-lactam and tetracycline antibiotics. They noted that these 59 
classes of compounds were very hydrophilic, suggesting that HILIC was highly appropriate for their 60 
analysis. Liquid chromatography combined with either mass spectrometry (LC-MS), fluorescence (FL) 61 
or ultraviolet detection (UV) is now widely adopted for TDM in many clinical laboratories. The main 62 
advantages of LC-MS for TDM are regarded as due to improved specificity and sensitivity compared 63 
with immunoassay [26]. In particular, antibiotic and antiretroviral drugs represent a class of 64 
medicines that need to be closely monitored for establishing efficacy in cases of multi-drug resistant 65 
infections and indeed also to monitor for patient compliance. One of the main analytical challenges 66 
with monitoring these compounds is that their physiochemical properties (i.e. logP, logD and pKa) 67 
vary widely; therefore it is important to select the most appropriate technique for obtaining good 68 
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chromatographic performance, retention and selectivity. This is particularly relevant when the 69 
monitoring of a drug of interest must be separated from isobaric interference [27]. For example, 70 
certain antiretroviral compounds are closely related to highly polar, endogenous nucleoside and 71 
nucleobase compounds such as uridine and cytosine. Often, antiretroviral and antibiotic therapies 72 
are administered in combination, making the choice for suitable chromatographic conditions for 73 
their measurement by a single method difficult. 74 
One of the main chromatographic difficulties when dealing with a sample containing compounds 75 
with widely different physicochemical properties is that gradient elution is usually required.  76 
Ultimately, the aim of any devised method is to provide adequate throughput in a reasonable time 77 
frame, while maintaining chromatographic resolution, at least at an adequate level for LC-MS. The 78 
adoption of gradient elution methods can be problematic, as the repeatability of the method can be 79 
compromised by the requirement to re-equilibrate the column between runs. This obviously limits 80 
the throughput of the procedure. In RP, around 20 column volumes of the initial eluent are required 81 
to reach full thermodynamic equilibrium [28]. However, excellent run-to-run repeatability has been 82 
demonstrated with only 2 column volumes of mobile phase whereas the time for full equilibrium can 83 
be reduced with the co-addition of ancillary solvents [28–30]. Gradient methods are often 84 
performed in HILIC, yet the amount of initial eluent required to achieve full equilibration is often 85 
quoted only anecdotally. However, it is believed that equilibration in HILIC takes around twice that 86 
of RP, yet very little data exists to substantiate these claims. 87 
The aim of this study was to investigate the applicability of HILIC for a range of 88 
physicochemically different antibiotic and antiretroviral compounds. These included antibiotic 89 
compounds mainly used in the treatment of tuberculosis: rifamycins (rifabutin/rifampicin), 90 
oxazolidazone (linezolid), beta-lactams (amoxicillin, flucoxacillin, meropenem, penicillin G, 91 
piperacillin, tazobactam), fluoroquinolones (ciprofloxacin/moxifloxacin), pyrimidine analogue 92 
(flucytosine), chloramphenicol, isoniazid, pyrazinamide, d-cycloserine, trimethoprim and 93 
sulfamethoxazole. The antiretroviral compounds studied were the guanosine analogues 94 
(acyclovir/ganciclovir). We chose these compounds partially due to their wide clinical usage,  range 95 
of log D values (mostly moderately positive to negative values, indicating potentially satisfactory 96 
retention in the HILIC mode) and also for the presence of UV chromophores. The work could be 97 
extended to other important classes of antibiotics such as aminogylcosides, however, due to their 98 
lack of appreciable conjugation would be more suited to mass spectrometric detection, which was 99 
not used in the present study. We initially determined which compounds were amenable to HILIC in 100 
terms of retention and selectivity by comparing bare silica, amide and urea phases. The bonded 101 
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phases were based on the same superficially porous particles as the bare silica phase.  We also 102 
wished to investigate peak shape effects for compounds containing certain functional groups. 103 
Finally, we performed a detailed study of gradient re-equilibration in HILIC, comparing bonded (urea 104 
and amide functionalised) and un-bonded HILIC phases at both low and moderate buffer 105 
concentrations adjusted to w
w
pH 3. Such a study highlights an important practical aspect for 106 
adopting HILIC in routine laboratories. This work builds on previous findings of column equilibration 107 
in HILIC both in isocratic and gradient modes [31,32]. 108 
2. Materials and Methods 109 
2.1 Chemicals and reagents 110 
Acetonitrile (HPLC gradient grade), ammonium formate (AF), ammonium citrate tribasic (AC), 111 
formic acid and toluene were purchased from Fisher Scientific (Loughborough, UK). D-Cycloserine, 112 
Rifampicin, Chloramphenicol, Ciprofloxacin, Isoniazid, Sulfamethoxazole, Amoxicillin, 5-113 
Fluorocytosine, Penicillin G sodium salt, Piperacillin sodium salt and Trimethoprim were obtained 114 
from Sigma-Aldrich (Poole, UK).  Flucloxacillin sodium salt was from EDQM, European 115 
Pharmacopoeia (Strasbourg, FR). Tazobactam sodium salt was from MicroConstants, Inc. (San Diego, 116 
USA). Moxifloxacin HCl from Bayer Pharma AG (Wuppertal, DE). Pyrazinamide, Rifabutin, 117 
Meropenem, Ganciclovir, Linezolid and Acyclovir from Sequoia Research Products (Pangbourne, UK). 118 
Stock solutions were prepared by dissolving each compound in 50:50 v/v acetonitrile:water + 0.1% 119 
formic acid at concentrations ranging from 2500 – 10000 mg/L. Individual solutions for injection of 120 
each compound at 50 mg L
-1
 were prepared from stock, diluting with 95:5 v/v acetonitrile:100 mM 121 
ammonium formate pH 3.0. Toluene at 5 mg L
-1
 was used as a void volume marker and prepared in 122 
the same diluent. Water at 18.2 mΩ was supplied from a Millipore Milli-Q purifier (Watford, UK). 123 
Mobile phases were prepared gravimetrically based on the density of water and acetonitrile at room 124 
temperature.  125 
 126 
2.2 Instrumentation and methodology 127 
A Waters Acquity Classic Ultra Performance Liquid Chromatograph (UPLC, Waters Corp., Milford, 128 
USA) was used for all experiments, comprising of a binary solvent manager (BSM), sample manager 129 
(SM) and a diode array detector (DAD) equipped with a 500 nL flow cell. Data acquisition and 130 
hardware control was performed using Empower2 (Waters Corp., Milford, USA). The three 131 
superficially porous columns used (all Accucore HILIC) were bare silica, polymer coated amide and 132 
urea bonded, 2.6 µm particle size (shell thickness 0.5 µm, Thermo Scientific, Runcorn, UK) that were 133 
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kind gifts from the manufacturer. The column dimensions used throughout were 100 x 2.1 mm ID. 134 
Columns were operated using a flow rate of 0.4 mL/min and held at 30 
o
C for all experiments. 1.0 µL 135 
injections were made throughout using full loop injection mode. LogD values at w
w
pH 3 were 136 
calculated using the average of three different software packages: ACD/I-Lab (ACD Labs, Toronto, 137 
Canada), Marvin (ChemAxon, Budapest, Hungary) and MedChem Designer (Simulations-Plus, 138 
Lancaster, USA). Quoted pKa values/values of solute charge were the average of results from the first 139 
two programs. Fig. 1 shows the structures and logDpH3 values for the compounds used in this study. 140 
Experiments on gradient retention time as a function of the re-equilibration time were performed 141 
according to the study of Carr et al. [28]. Briefly, this involved an initial sequence of six control 142 
gradients, five of which included 22.3 mins equilibration time, representing full equilibration (see 143 
3.3). The sixth control run concluded with a specified equilibration time (e.g. 4.3 min). These runs 144 
were followed by four (n=4) experimental gradient runs at the same re-equilibration times. The 145 
experimental runs were followed by two control runs, the first of which used a full equilibration time 146 
(22.3 min.) and the second using the next equilibration time in the sequence (e.g. 7.3 min.) A further 147 
sequence of 4 experimental gradient runs was then performed, and the process repeated. Data were 148 
gathered for experimental re-equilibration times of 4.3, 7.3, 9.3, 12.3, 17.3, 22.3 and 27.3 minutes. 149 
The relative standard deviation (%RSD) was calculated for each compound in the gradient (tG=10 150 
mins) after different re-equilibration times. Note that the equilibration time may well depend on the 151 
initial solvent composition as well as the range of concentration used during the gradient. The 152 
injection cycle time was 2.3 minutes, which was included in the stated re-equilibration times. This 153 
cycle time is quite long, being a consequence of the use of the full loop injection mode, which was 154 
employed to obtain maximum precision. Cycle times are typically much shorter for systems that 155 
used the flow through needle injection process [32].  The gradient time (tG) used throughout the 156 
study was always 10 minutes after which the mobile phase was immediately returned to the initial 157 
conditions. Mobile phases were typically flushed through the column for at least 1 hour prior to any 158 
experiments being performed. The mobile phases for gradient re-equilibration experiments were A: 159 
95% ACN, 5 mM overall ammonium formate pH 3 and B: 60% ACN, 5 mM overall ammonium 160 
formate pH 3. 161 
 162 
3. Results and discussion 163 
3.1 Retention comparison between bare silica, amide and urea phases. 164 
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 Isocratic retention data for the 20 structurally diverse antibiotic and antiretroviral compounds were 165 
collected at both 90% and 95% ACN containing 5 mM overall AF pH 3 on bare silica, amide and urea 166 
columns. 5 mM AF pH 3 was employed as this buffer concentration gives good peak shapes in HILIC 167 
[33,34] as opposed to sole use of formic acid (e.g. 0.1% v/v), despite the latter being favoured 168 
sometimes due to reduced suppression of solute signal intensity in electrospray mass spectrometry. 169 
Fig. 2 shows the large differences in k between the different columns. Clearly, HILIC is not a suitable 170 
procedure for linezolid, pyrazinamide, and chloramphenicol (which are neutral over the pH range 2-171 
9) as their k < 1 on all columns. This result was not unexpected for linezolid and chloramphenicol, as 172 
their logDpH3 values are > 0.5, indicating low hydrophilicity. Sulfamethoxazole was poorly retained 173 
under the conditions used, but has the possibility of using ionic interactions to increase retention, 174 
becoming negatively charged at pH >5. Pyrazinamide also has poor retention although is more 175 
hydrophilic (logDpH3 -0.91) indicating that retention of this compound might be achieved solely by 176 
the partitioning mechanism. Isoniazid (LogD pH3 -1.28), which is structurally similar to pyrazinamide 177 
gave appreciably higher retention on the three stationary phases. Its higher retention may be 178 
explained by its greater hydrophilicity and its positive charge in the mobile phase (estimated as 179 
+0.9), leading to the possibility of ionic interactions with ionised column silanols. In comparison, 180 
pyrazinamide was estimated to have zero charge in the mobile phase used. There is not always a 181 
good correlation between retention and logD values [12]. The correlation coefficients (R) of logDpH3 182 
versus log k (at 90% ACN) for all compounds on bare silica, amide and urea phases were only 183 
moderate at 0.67, 0.78 and 0.60 respectively, which further emphasises the difficulty in predicting 184 
retention in HILIC when considering a partition mechanism only. Moreover, there was disagreement 185 
between the predicted logDpH3 values for pyrazinamide with -0.68, -1.23 and -0.80 being obtained 186 
from ACD, Marvin and MedChem Designer programs respectively. As noted previously [13], variation 187 
between predictive software packages further complicates retention correlation when using 188 
calculated log D values. 189 
The highest retention factors observed on all phases were for meropenem and amoxicillin. 190 
These compounds are very hydrophilic with logDpH3 values of -3.21 and -2.81 respectively. At a lower 191 
concentration of 90% ACN, meropenem was still very strongly retained on the bare silica phase (k = 192 
63.1) although with much lower retention on the amide (k = 37.2) and significantly less on the urea 193 
phases (k = 10.9). Conversely, amoxicillin showed the strongest retention on the amide phase (k = 194 
28.9) under the same conditions compared with the bare silica and urea phases. The data suggests 195 
that stronger ionic retention is experienced by meropenem (as ionic retention is high on bare silica 196 
phases). Indeed, the calculation programs suggest that meropenem may carry a slightly greater 197 
positive charge (+0.6) than amoxicillin (+0.5) at w
w
 pH 3.0, which in combination with its more 198 
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negative log D value, may explain its greater retention on silica. Amoxicillin and meropenem gave 199 
excessive retention at 95% ACN on all of the columns, so k data was not obtained. The retention of 200 
ganciclovir and acyclovir (neutral, nucleoside analogues) was stronger on the amide column than 201 
with the bare silica column. It has been shown [9] that amide phases have significantly thicker water 202 
layers than bare silica columns encouraging a partition retention mechanism. Interestingly, however, 203 
retention for ganciclovir and acyclovir was only marginally larger on the urea phase than on bare 204 
silica.  205 
Fig. 3 indicates the correlation in k between the bare silica, amide and urea phases using 90% 206 
ACN-buffer. Interestingly, the difference in selectivity of the bare silica versus the amide phase in 207 
this study was smaller than data from previous findings [13], although this manufacturer’s phases 208 
have not been examined previously. The difference in selectivity when comparing amide and urea 209 
phases was also small. Note however that the R values shown in the Figure should be treated with 210 
some caution, as the points corresponding to higher k values are given much greater weight than the 211 
other data points. However, larger differences in selectivity were found between the bare silica and 212 
urea phases that can be explained by the very strong retention of meropenem, ciprofloxacin and 213 
moxifloxacin on the former. Rifamycin compounds were reasonably well retained on both bare silica 214 
and urea phases, whereas rifabutin had a k < 1 on the amide column. The selectivity factors (α) for 215 
rifampicin and rifabutin on the urea and bare silica phases were 1.63 and 0.52 respectively. All of the 216 
β-lactam and rifamycin antibiotics, except for amoxicillin and meropenem, were more retained on 217 
the urea than on the amide phase. This might indicate some preferential selectivity from the urea 218 
bonding towards structural features on these compounds. Surprisingly, flucytosine (neutral, 219 
pyrimidine analogue) was retained more strongly on the urea phase than on either bare silica or the 220 
amide phases. This might be considered unusual since the neutral guanosine-analogues acyclovir 221 
and ganciclovir showed the strongest retention on the amide column, as seen previously with other 222 
nucleosides in HILIC [13,33]. 223 
 In summary, HILIC has been shown to be broadly applicable for the retention of antibiotic 224 
and antiretroviral compounds using either bare silica, amide or urea bonded phases. Overall, using  225 
95% ACN-buffer the bare silica column was the most retentive phase with an average k of the 226 
antibiotic compounds of 9.6 compared with the amide and urea phases, which gave average k 6.4 227 
and 4.3 respectively. However, due to the wide differences in retention it would be necessary to use 228 
gradient elution to elute all retained compounds within a practical analysis time (see below).  229 
 230 
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3.2 Asymmetric peaks: addition of citrate 231 
Poor peak shapes were seen on all phases for the fluoroquinolones ciprofloxacin and 232 
moxifloxacin as well as for d-cycloserine as illustrated for the bare silica phase in Fig. 4 when using 5 233 
mM AF pH 3 in 90% ACN AF.  Fig. 5 shows the same after the co-addition of citrate.  All compounds 234 
showed some improvement in peak shape. For d-cycloserine, the tailing peak becomes almost 235 
symmetrical on this addition. Interestingly, there was a considerable reduction in retention (Fig. 6) 236 
for the fluoroquinolones upon co-addition of citrate, whereas very little change was seen for d-237 
cycloserine. This reduction in retention may be due to citrate shielding strong secondary interactions 238 
complicit in the poor peak asymmetry seen with these compounds. Citrate is known to strongly 239 
chelate metal oxides in aqueous systems, particularly those of iron(III) [35]. While ethylene diamine 240 
tetraacetic acid (EDTA) might under some circumstances be a better complexing agent, it is rather 241 
insoluble in HILIC mobile phases containing high proportions of ACN [36]. We postulate that both 242 
fluoroquinolones and d-cycloserine undergo chelation-based interactions with labile metal oxides 243 
within the chromatographic apparatus. The quinolone group has been shown to have metal oxide 244 
chelation properties [37]. There are many potential sources of metal contamination within a 245 
chromatographic system. As shown by Euerby et al. [38,39] storage of columns in acetonitrile can 246 
result in the leaching of metals. Moreover, the presence of stainless steel column packing frits could 247 
also be significant, as their surface area is significantly larger in comparison to the wetted parts of 248 
metal connection tubing. Carr et al. [40] showed that corrosion of stainless steel column frits in 249 
acidic mobile phases results in the release of metal-oxides such as iron(II)/iron(III). Also, it has been 250 
shown elsewhere [41] that replacement of stainless steel frits with polyethylene-type were 251 
beneficial for the RP chromatography of metal-chelating phosphorylated compounds. It is therefore 252 
likely that available metal oxides become immobilised on silanol groups and thus act as metal affinity 253 
exchange sites. Several manufacturers now offer biocompatible instruments that are supposedly 254 
inert to metal oxide-solute interactions [42,43] which could be more suitable for the analysis of 255 
sensitive antibiotics. However, no previous reports on the interaction of d-cycloserine with metals 256 
could be found. A different explanation for the poor peak shape of d-cycloserine could be an on-257 
column dimerization reaction, which becomes inhibited by the co-addition of citrate. It has been 258 
shown [44] that acetonitrile promotes the dimerization of d-cycloserine whereas this reaction is 259 
strongly inhibited in methanol. It is thought that methanol protects against nucleophilic attack on 260 
the carbonyl group through electrophilic solvation of the α-amino position. 261 
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It is possible that peak shapes might have been improved merely by increasing the concentration 262 
of ammonium formate buffer, although previous work did not demonstrate a strong dependence of 263 
peak shape on this parameter [45]. 264 
To summarise, fluoroquinolones showed evidence of stronger affinity towards system metal 265 
oxides in comparison to d-cycloserine that were not completely removed even after the co-addition 266 
of citrate. Therefore, the stainless steel column/frits/HPLC system used here might not be optimum 267 
for the analysis of fluoroquinolone antibiotics. Certainly, further work needs to be done to explore 268 
alternative operating conditions to further improve the peak shapes seen here for fluoroquinolones. 269 
An improved HILIC method for the analysis of these compounds could be useful as the logDpH3 values 270 
of ciprofloxacin and moxifloxacin are -2.19 and -1.46 respectively, indicating they are considerably 271 
hydrophilic. 272 
3.3 Investigation of gradient re-equilibration in HILIC  273 
As the k values of retained antibiotic and antiretroviral compounds were impractically different 274 
under isocratic conditions, we studied the use of gradient analysis. We chose bare silica and amide 275 
phases in this study with initial starting conditions of 95% ACN-buffer. The effect of buffer at both 276 
low (2 mM AF) and moderate (5 mM AF) concentrations was also investigated using the bare silica 277 
phase only. Equivalent buffer concentrations were maintained in both the A and B bottles to avoid 278 
introducing a salt concentration gradient. The test sample contained isoniazid, rifabutin, 279 
trimethoprim, flucytosine, acyclovir, ganciclovir and amoxicillin. Table 1 shows a summary of the 280 
repeatability of retention as a function of the different re-equilibration times for each of the 281 
investigated columns and conditions used. Notably, very good repeatability was observed regardless 282 
of the re-equilibration time, as long as the equilibration period was strictly the same between 283 
replicates, even for an equilibration time of only 4.3 min. This result is broadly in agreement with the 284 
work of Shollenberger and Bell and our previous studies in HILIC [31,32]. Carr et al. [28] also 285 
observed the same degree of repeatability under reversed-phase conditions. Fig. 7 shows 286 
chromatograms obtained at different gradient re-equilibration times on the bare silica column using 287 
5 mM AF. It appears that while the retention of some peaks (e.g. amoxicillin (peak 7) is reasonably 288 
independent of equilibration time, the retention of others (e.g. Rifabutin (peak 2) shows 289 
considerably greater dependence. Figs. 8 a-c show the differences between the control value and 290 
the experimental retention times for each re-equilibration time and each solute. A positive or 291 
negative value on the y-axis indicates insufficient equilibration of the column (compared with “full 292 
equilibration”) resulting in a loss or gain of retention compared with the control run. The results in 293 
Fig. 7 and Fig. 8 are somewhat surprising, as it might be expected that insufficient equilibration of 294 
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the column would result universally in reduced solute retention times, as residues of the strong 295 
solvent remain in the column. For compounds that are neutral under the analysis conditions 296 
(flucytosine, acyclovir, ganciclovir), there were indeed losses in retention, which became worse with 297 
increasingly shorter re-equilibration times. Surprisingly, the basic compounds (rifabutin, 298 
trimethoprim) showed an increase in retention at shorter equilibration times, similar to previous 299 
findings [31,32]. Less divergence from the control run was seen for all compounds with the amide 300 
column. The situation is likely to be more complex in HILIC than RP, as changing the mobile phase 301 
from 95% ACN to a more aqueous composition results also in variation of the thickness of the water 302 
layer held at the stationary phase surface [8], as well as increasing the solvent strength. 303 
Furthermore, over the course of the gradient, the variation in the water layer thickness could result 304 
in changes in the distribution of buffer components away from the stationary phase surface into the 305 
bulk mobile phase region. It has been shown [13,21,34] that decreasing buffer concentration in HILIC 306 
results in reduced retention for neutral compounds, which is thought to be due to decreased 307 
thickness of the water layer. Alternatively, increased retention for basic compounds occurs at lower 308 
buffer concentration due to reduced competition for ion-exchange interactions [44]. These 309 
explanations correlate well with our results above.  310 
A further factor influencing the equilibration process might be the absolute retention of 311 
each solute on the column. Only small changes in gradient retention time were observed for 312 
amoxicillin, which was the last eluting peak in the chromatogram on both columns under all 313 
conditions. We speculate that strongly retained compounds remain mostly immobile on the front of 314 
the column until the last stages of the gradient (at higher aqueous concentration values), and are 315 
thus unaffected by the exact equilibration state of the column at the start of a fresh gradient, when 316 
only a weak eluent is present. Similarly, the first peak (isoniazid) may be readily mobile through the 317 
column in a range of solvent compositions around that of the starting conditions (95% ACN–buffer), 318 
resulting again in approximately constant retention with equilibration time.  319 
 The data also indicates that bare silica and amide phases require a similar time/amount of 320 
mobile phase volume to have passed through in order to achieve full equilibration (Fig, 8). The data 321 
points converge into an asymptote indicating that full column equilibration has been established for 322 
each of the conditions. This point (22.3 mins) for the bare silica column represents around 40.5 323 
column volumes (8.9 mL). Longer column equilibration (27.3 mins) seems unnecessary using these 324 
particular conditions, but can be strongly dependent on the nature of both the column and the 325 
mobile phase [32]. Furthermore, using lower buffer concentrations (Fig. 8 b-c) neither increased nor 326 
reduced the re-equilibration time needed for full equilibration to be achieved. Fig. 9 a-c show plots 327 
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of control-experimental gradient retention time against gradient retention time for the 7 solutes at 328 
the 7 different equilibration times. Fig. 9a clearly indicates that the differences between control and 329 
experimental retention on the amide column (as exhibited by the smaller spread of the diagonal 330 
lines) for the majority of solutes were much less affected by re-equilibration time than on the silica 331 
column (Fig. 9b and 9c). Overall, the basic compounds (rifabutin and trimethoprim) showed the 332 
greatest differences from the control runs on all columns and buffer conditions. This is perhaps 333 
unsurprising as the retention of basic compounds is more sensitive to possible transient alterations 334 
in buffer component distribution caused by the gradient than for pseudo-neutral or neutral 335 
compounds [34].  336 
 Finally, it would be possible to increase mobile phase flow during the equilibration step to 337 
further reduce equilibration time, as shown previously [32]. Note however, there did not seem to be 338 
a direct proportionality between equilibration time and flow rate in this step. 339 
4. Conclusions 340 
HILIC is broadly suitable for the analysis of many antibiotic and antiretroviral compounds with 341 
widely different physiochemical properties. The retention properties of three different superficially 342 
porous particle packed columns (bare silica, amide and urea bonded phases) were evaluated for 343 
these solutes under typical isocratic HILIC conditions. The selectivity, particularly of bare silica and 344 
urea phases, was different, indicating a useful degree of orthogonality for method development. 345 
There was much less difference in selectivity between the bare silica and amide phases. 346 
Fluoroquinolones and d-cycloserine gave severe peak tailing on all columns, attributable to on 347 
column metal-oxide interactions. This was likely due to chelation between the quinolone group 348 
(fluoroquinolones) or by on column dimerization (d-cycloserine) promoted by metal-oxides residing 349 
on the stationary phase. The co-addition of citrate proved moderately effective in improving peak 350 
shapes for fluoroquinolones, whereas the peak of d-cycloserine was considerably improved. 351 
The wide differences in retention factors seen under isocratic conditions prompted an 352 
investigation into the effect of gradient re-equilibration time in HILIC. In order to obtain full 353 
equilibration in HILIC around 40 column volumes were needed between each run. Indeed, the time 354 
taken to achieve full equilibration was significantly longer than that needed to perform the 355 
separation (tG = 10 minutes, re-equilibration e.g = 22.3 minutes for the silica column). The progress 356 
of full equilibration was found to be largely unaffected by buffer concentration. Full equilibration 357 
time appears to be about twice that required in reversed-phase chromatography and is an obvious 358 
practical disadvantage of HILIC, with some consequences for gradient elution. Nevertheless, it was 359 
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shown that short gradient re-equilibration times of only a few minutes could be used with excellent 360 
retention repeatability, thus offering a practical solution to the problem. Separation selectivity in 361 
this “partial” or “pseudo-equilibrium” environment was shown to be considerably affected by 362 
equilibration time, which should therefore be held strictly constant for consistent results to be 363 
obtained.   364 
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6. Legend to Figures 497 
 498 
Fig. 1 Structures and logDpH3 of test compounds. 499 
 500 
Fig.2 Retention factors (k) for test compounds on bare silica, amide and urea phases using either 501 
90% (top) or 95% (bottom) ACN AF w
w
pH3. Meropenem and amoxicillin not determined at 95% ACN 502 
due to excessively high retention. 503 
 504 
Fig. 3 k versus k plots for different columns using 5 mM AF w
w
pH 3.0 in 90% ACN for bare silica, 505 
amide and urea phases. 506 
 507 
Fig. 4 Chromatograms for moxifloxacin (a) ciprofloxacin (b) and cycloserine (c) on the bare silica 508 
phase. Mobile phase: 90% ACN, 5 mM overall ammonium formate adjusted to w
w
pH 3 with formic 509 
acid. Moxifloxacin λmax = 295 nm, ciprofloxacin λmax = 280 nm and cycloserine λmax = 215 nm. 510 
 511 
Fig. 5 Chromatograms for moxifloxacin (a) ciprofloxacin (b) and cycloserine (c) on the bare silica 512 
phase after the co-addition of citrate. Mobile phase: 90% ACN, 2.5 mM overall ammonium formate, 513 
2.5 mM ammonium citrate adjusted to w
w
pH 3 with formic acid. 514 
   515 
Fig. 6 Retention factor (a), asymmetry factor (b) and peak efficiency (c) measurements for 516 
moxifloxacin, ciprofloxacin and d-cycloserine on the bare silica column using 90% ACN with either AF 517 
or AF/AC. 518 
 519 
Fig. 7 Chromatograms obtained of the gradient test mix on the bare silica column using different re-520 
equilibration times. Linear gradient from 100% A to 70% A, 5 mM buffer (effectively 95% ACN-buffer  521 
to 84.5% ACN-buffer) in 10 min. Peak identities: (1) Isoniazid (2) Rifabutin (3) Trimethoprim (4) 522 
Flucytosine (5) Acyclovir (6) Ganciclovir (7) Amoxicillin. λmax = 275 nm. 523 
 524 
Fig. 8 Effect of re-equilibration time on the difference between experimental and control gradient 525 
retention times. (a) amide Linear gradient from 100% A to 60% A, 5 mM buffer(effectively 95 % ACN-526 
buffer to 81 % ACN-buffer) in 10 min. (b) bare silica Linear gradient from 100% A to 70% A, 5 mM 527 
buffer) (c) bare silica (Linear gradient from 100% A to 70% A, 2 mM buffer). The mobile phases used 528 
were as indicated in section 1.2. 529 
 530 
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Fig. 9 Effect of gradient re-equilibration time on the difference between experimental and control 531 
gradient retention times as a function of retention time. Conditions were as in Fig. 8 for (a), (b) and 532 
(c) respectively. 533 
 534 
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%RSD (n = 4) Amide (5 mM)       
        
Re-Eq. Time (mins) Rifabutin Isoniazid Trimethoprim Flucytosine Acyclovir Ganciclovir Amoxicillin 
4.3 0.080 0.046 0.039 0.034 0.134 0.218 0.094 
7.3 0.047 0.048 0.041 0.056 0.100 0.121 0.077 
9.3 0.152 0.024 0.149 0.062 0.079 0.101 0.076 
12.3 0.459 0.067 0.392 0.079 0.076 0.062 0.045 
17.3 0.123 0.013 0.114 0.018 0.023 0.033 0.032 
22.3 0.014 0.013 0.020 0.015 0.003 0.006 0.004 
27.3 0.007 0.009 0.017 0.051 0.044 0.041 0.031 
        
%RSD (n = 4) Bare silica (5 mM)      
        
Re-Eq. Time (mins) Rifabutin Isoniazid Trimethoprim Flucytosine Acyclovir Ganciclovir Amoxicillin 
4.3 0.102 0.335 0.113 0.028 0.057 0.077 0.200 
7.3 0.249 0.323 0.246 0.043 0.176 0.307 0.158 
9.3 0.123 0.192 0.216 0.028 0.168 0.066 0.137 
12.3 0.187 0.135 0.041 0.070 0.177 0.086 0.125 
17.3 1.028 0.123 0.841 0.024 0.030 0.037 0.068 
22.3 0.056 0.044 0.043 0.030 0.017 0.012 0.005 
27.3 0.070 0.014 0.045 0.019 0.019 0.027 0.036 
        
%RSD (n = 4) Bare silica (2 mM)      
        
Re-Eq. Time (mins) Rifabutin Isoniazid Trimethoprim Flucytosine Acyclovir Ganciclovir Amoxicillin 
4.3 0.094 0.159 0.109 0.034 0.052 0.053 0.250 
7.3 0.256 0.116 0.269 0.040 0.055 0.071 0.190 
9.3 0.145 0.068 0.135 0.040 0.050 0.078 0.163 
12.3 0.109 0.114 0.098 0.025 0.033 0.056 0.119 
17.3 0.124 0.064 0.320 0.040 0.157 0.020 0.223 
22.3 0.035 0.056 0.026 0.027 0.021 0.017 0.011 
27.3 0.036 0.039 0.035 0.040 0.034 0.036 0.066 
 
Table 1 Relative standard deviation (RSD) of gradient retention time using different re-equilibration times on amide and bare silica columns. 
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• HILIC is a suitable method for HPLC analysis of a wide range of 
antibiotics. 
• Selectivity of analysis can change dependent on the stationary phase. 
• Citrate improves peak shape of some solutes by reducing metal oxide 
interactions. 
• Full equilibration times are much longer in HILIC than in RP. 
• Repeatable partial equilibration in gradient elution achieved in < 5 min. 
